bioAffinity Technologies to present CyPath® Lung processing research at CHEST 2025

bioAffinity Technologies, Inc.

Poster presented Oct 22, 2025 by Rossella Titone, PhD at poster board #4324.
Study evaluates sputum storage and shipping temperature effects on flow cytometry outcomes.
Research supports protocols for home-collected sputum samples with two-day result turnaround.
CyPath® Lung previously reported 92% sensitivity, 87% specificity, 88% accuracy in early-stage lung cancer detection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.